Advancing the management and control of typhoid fever: A review of the historical role of human challenge studies

Journal of Infection

Volumn 68, Issue 5, 2014, Pages 405-418

  Waddington, Claire S ^a   Darton, Thomas C ^a   Woodward, William E ^c   Angus, Brian ^b   Levine, Myron M ^d   Pollard, Andrew J ^a  

^a CHURCHILL HOSPITAL   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^d University of Maryland School of Medicine Center for Vaccine Development   (United States)

Author keywords

Controlled human infection; Enteric infection; Human challenge; Quailes strain; Salmonella Typhi; Typhoid fever

Indexed keywords

CHLORAMPHENICOL; INACTIVATED VACCINE; TYPHOID VACCINE; TYPHOID PARATYPHOID VACCINE;

ANTIBODY TITER; BACTERIAL IMMUNITY; BACTERIAL STRAIN; BACTERIAL VIRULENCE; COLONY FORMING UNIT; FECES CULTURE; HISTOPATHOLOGY; HOST PATHOGEN INTERACTION; HUMAN; INFECTION CONTROL; INFECTION PREVENTION; NONHUMAN; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; REVIEW; TEMPERATURE MEASUREMENT; TYPHOID FEVER; VACCINE PRODUCTION; HISTORY; HUMAN EXPERIMENT; IMMUNOLOGY; ISOLATION AND PURIFICATION; SALMONELLA ENTERICA SUBSP. ENTERICA SEROVAR TYPHI;

HISTORY, 20TH CENTURY; HUMANS; SALMONELLA TYPHI; THERAPEUTIC HUMAN EXPERIMENTATION; TYPHOID FEVER; TYPHOID-PARATYPHOID VACCINES;

EID: 84897959556     PISSN: 01634453     EISSN: 15322742     Source Type: Journal    
DOI: 10.1016/j.jinf.2014.01.006     Document Type: Review

References (103)

1. Buckle G.C., Walker C.L., Black R.E. Typhoid fever and paratyphoid fever: systematic review to estimate global morbidity and mortality for 2010. J Glob Health 2012, 2(1):10401. PubMed PMID: 23198130. Pubmed Central PMCID: 3484760. Epub 2012/12/01. eng.
2. Hope T., McMillan J. Challenge studies of human volunteers: ethical issues. J Med Ethics 2004, 30(1):110-116. PubMed PMID: 14872087. Pubmed Central PMCID: 1757139. Epub 2004/02/12. eng.
3. Academy of Medical Sciences Microbial challenge studies of human volunteers 2005, London. http://www.acmedsci.ac.uk/index.php?pid=99%26puid=18.
4. Jefferson T. Microbial challenge studies - a challenge worth accepting. Lancet 2005, 366(9485):531-533. PubMed PMID: 16099277. Epub 2005/08/16. eng.
5. Cash R.A., Music S.I., Libonati J.P., Craig J.P., Pierce N.F., Hornick R.B. Response of man to infection with Vibrio cholerae. II. Protection from illness afforded by previous disease and vaccine. J Infect Dis 1974, 130(4):325-333. PubMed PMID: 4443613. Epub 1974/10/01. eng.
6. Losonsky G.A., Tacket C.O., Wasserman S.S., Kaper J.B., Levine M.M. Secondary Vibrio cholerae-specific cellular antibody responses following wild-type homologous challenge in people vaccinated with CVD 103-HgR live oral cholera vaccine: changes with time and lack of correlation with protection. Infect Immun 1993, 61(2):729-733. PubMed PMID: 8423098. Pubmed Central PMCID: 302786. Epub 1993/02/01. eng.
7. Tacket C.O., Cohen M.B., Wasserman S.S., Losonsky G., Livio S., Kotloff K., et al. Randomized, double-blind, placebo-controlled, multicentered trial of the efficacy of a single dose of live oral cholera vaccine CVD 103-HgR in preventing cholera following challenge with Vibrio cholerae O1 El tor inaba three months after vaccination. Infect Immun 1999, 67(12):6341-6345. PubMed PMID: 10569747. Pubmed Central PMCID: 97039. Epub 1999/11/24. eng.
8. DuPont H.L., Hornick R.B., Snyder M.J., Libonati J.P., Formal S.B., Gangarosa E.J. Immunity in shigellosis. I. Response of man to attenuated strains of Shigella. J Infect Dis 1972, 125(1):5-11. PubMed PMID: 4550417. Epub 1972/01/01. eng.
9. Kotloff K.L., Losonsky G.A., Nataro J.P., Wasserman S.S., Hale T.L., Taylor D.N., et al. Evaluation of the safety, immunogenicity, and efficacy in healthy adults of four doses of live oral hybrid Escherichia coli-Shigella flexneri 2a vaccine strain EcSf2a-2. Vaccine 1995, 13(5):495-502. PubMed PMID: 7639017. Epub 1995/04/01. eng.
10. Kotloff K.L., Noriega F., Losonsky G.A., Sztein M.B., Wasserman S.S., Nataro J.P., et al. Safety, immunogenicity, and transmissibility in humans of CVD 1203, a live oral Shigella flexneri 2a vaccine candidate attenuated by deletions in aroA and virG. Infect Immun 1996, 64(11):4542-4548. PubMed PMID: 8890204. Pubmed Central PMCID: 174410. Epub 1996/11/01. eng.
11. Levine M.M., Woodward W.E., Formal S.B., Gemski P., DuPont H.L., Hornick R.B., et al. Studies with a new generation of oral attenuated shigella vaccine: Escherichia coli bearing surface antigens of Shigella flexneri. J Infect Dis 1977, 136(4):577-582. PubMed PMID: 333041. Epub 1977/10/01. eng.
12. Levine M.M., Bergquist E.J., Nalin D.R., Waterman D.H., Hornick R.B., Young C.R., et al. Escherichia coli strains that cause diarrhoea but do not produce heat-labile or heat-stable enterotoxins and are non-invasive. Lancet 1978, 1(8074):1119-1122. PubMed PMID: 77415. Epub 1978/05/27. eng.
13. McKenzie R., Bourgeois A.L., Frech S.A., Flyer D.C., Bloom A., Kazempour K., et al. Transcutaneous immunization with the heat-labile toxin (LT) of enterotoxigenic Escherichia coli (ETEC): protective efficacy in a double-blind, placebo-controlled challenge study. Vaccine 2007, 25(18):3684-3691. PubMed PMID: 17313998. Epub 2007/02/23. eng.
14. McKenzie R., Darsley M., Thomas N., Randall R., Carpenter C., Forbes E., et al. A double-blind, placebo-controlled trial to evaluate the efficacy of PTL-003, an attenuated enterotoxigenic E. coli (ETEC) vaccine strain, in protecting against challenge with virulent ETEC. Vaccine 2008, 26(36):4731-4739. PubMed PMID: 18602960. Epub 2008/07/08. eng.
15. Tribble D.R., Baqar S., Carmolli M.P., Porter C., Pierce K.K., Sadigh K., et al. Campylobacter jejuni strain CG8421: a refined model for the study of Campylobacteriosis and evaluation of Campylobacter vaccines in human subjects. Clin Infect Dis 2009, 49(10):1512-1519. PubMed PMID: 19842970. Epub 2009/10/22. eng.
16. Sauerwein R.W., Roestenberg M., Moorthy V.S. Experimental human challenge infections can accelerate clinical malaria vaccine development. Nat Rev Immunol 2011, 11(1):57-64. PubMed PMID: 21179119.
17. Stoute J.A. Malaria sporozoite challenge model comes of age. Pathog Glob health 2012, 106(6):320. PubMed PMID: 23182133.
18. Church L.W., Le T.P., Bryan J.P., Gordon D.M., Edelman R., Fries L., et al. Clinical manifestations of Plasmodium falciparum malaria experimentally induced by mosquito challenge. J Infect Dis 1997, 175(4):915-920. PubMed PMID: 9086149.
19. Sanderson F., Andrews L., Douglas A.D., Hunt-Cooke A., Bejon P., Hill A.V. Blood-stage challenge for malaria vaccine efficacy trials: a pilot study with discussion of safety and potential value. Am J Trop Med Hyg 2008, 78(6):878-883. PubMed PMID: 18541763.
20. Durbin A.P., Whitehead S.S. The dengue human challenge model: has the time come to accept this challenge?. J Infect Dis 2013, 207(5):697-699. PubMed PMID: 23225898.
21. Sun W., Eckels K.H., Putnak J.R., Lyons A.G., Thomas S.J., Vaughn D.W., et al. Experimental dengue virus challenge of human subjects previously vaccinated with live attenuated tetravalent dengue vaccines. J Infect Dis 2013, 207(5):700-708. PubMed PMID: 23225894.
22. Fries L.F., Dillon S.B., Hildreth J.E., Karron R.A., Funkhouser A.W., Friedman C.J., et al. Safety and immunogenicity of a recombinant protein influenza A vaccine in adult human volunteers and protective efficacy against wild-type H1N1 virus challenge. J Infect Dis 1993, 167(3):593-601. PubMed PMID: 8440931.
23. Treanor J., Wright P.F. Immune correlates of protection against influenza in the human challenge model. Dev Biol 2003, 115:97-104. PubMed PMID: 15088780.
24. Carrat F., Vergu E., Ferguson N.M., Lemaitre M., Cauchemez S., Leach S., et al. Time lines of infection and disease in human influenza: a review of volunteer challenge studies. Am J Epidemiol 2008, 167(7):775-785. PubMed PMID: 18230677.
25. Killingley B., Enstone J.E., Greatorex J., Gilbert A.S., Lambkin-Williams R., Cauchemez S., et al. Use of a human influenza challenge model to assess person-to-person transmission: proof-of-concept study. J Infect Dis 2012, 205(1):35-43. PubMed PMID: 22131338.
26. Gilman R.H., Hornick R.B., Woodard W.E., DuPont H.L., Snyder M.J., Levine M.M., et al. Evaluation of a UDP-glucose-4-epimeraseless mutant of Salmonella typhi as a liver oral vaccine. J Infect Dis 1977, 136(6):717-723. PubMed PMID: 925379.
27. Gotuzzo E., Butron B., Seas C., Penny M., Ruiz R., Losonsky G., et al. Safety, immunogenicity, and excretion pattern of single-dose live oral cholera vaccine CVD 103-HgR in Peruvian adults of high and low socioeconomic levels. Infect Immun 1993, 61(9):3994-3997. PubMed PMID: 8359923. Pubmed Central PMCID: 281106. Epub 1993/09/01. eng.
28. Hornick R.B., Greisman S.E., Woodward T.E., DuPont H.L., Dawkins A.T., Snyder M.J. Typhoid fever: pathogenesis and immunologic control. N Engl J Med 1970, 283(13):686-691. PubMed PMID: 4916913. Epub 1970/09/24. eng.
29. Woodward W.E. Volunteer studies of typhoid fever and vaccines. Trans R Soc Trop Med Hyg 1980, 74(5):553-556. PubMed PMID: 7210105. Epub 1980/01/01. eng.
30. Levine M.M., Tacket C.O., Sztein M.B. Host-Salmonella interaction: human trials. Microbes Infect 2001, 3(14-15):1271-1279. PubMed PMID: 11755415. eng.
31. Sprinz H., Gangarosa E.J., Williams M., Hornick R.B., Woodward T.E. Histopathology of the upper small intestines in typhoid fever. Biopsy study of experimental disease in man. Am J Dig Dis 1966, 11(8):615-624. PubMed PMID: 5943767. Epub 1966/08/01. eng.
32. Dupont H.L., Hornick R.B., Snyder M.J., Dawkins A.T., Heiner G.G., Woodward T.E. Studies of immunity in typhoid fever. Protection induced by killed oral antigens or by primary infection. Bull World Health Organ 1971, 44(5):667-672. PubMed PMID: 5316750. Pubmed Central PMCID: 2427859. Epub 1971/01/01. eng.
33. Wright A.E. On the association of serous haemorrhages with conditions of defective blood-coagulability. Lancet 1896, 807-809.
34. Tigertt W.D. The initial effort to immunize American soldier volunteers with typhoid vaccine. Mil Med 1959, 124(5):342-349. PubMed PMID: 13656515. Epub 1959/05/01. eng.
35. Hornick R.B., Woodward T.E. Appraisal of typhoid vaccine in experimentally infected human subjects. Trans Am Clin Climatol Assoc 1967, 78:70-78. PubMed PMID: 6028241. Pubmed Central PMCID: 2441150. Epub 1967/01/01. eng.
36. Hornick R.B., Woodward W.E., Greisman S.E., Doctor T.E. Woodward's legacy: from typhus to typhoid fever. Clin Infect Dis 2007, 45(Suppl. 1):S6-S8. PubMed PMID: 17582572. Epub 2007/07/14. eng.
37. Hornick R.B., Greisman S.E., Woodward T.E., DuPont H.L., Dawkins A.T., Snyder M.J. Typhoid fever: pathogenesis and immunologic control. 2. N Engl J Med 1970, 283(14):739-746. PubMed PMID: 4916916.
38. Sabin A.B. Behaviour of Chimpanzee-avirulent poliomyelitis viruses in experimentally infected human volunteers. Br Med J (Clin Res Ed) 1955, 2(4932):160-162. PubMed PMID: 20788449. Pubmed Central PMCID: 1980369. Epub 1955/07/16. eng.
39. Clyde D.F., McCarthy V.C., Miller R.M., Hornick R.B. Specificity of protection of man immunized against sporozoite-induced falciparum malaria. Am J Med Sci 1973, 266(6):398-403. PubMed PMID: 4590095. Epub 1973/12/01. eng.
40. Clyde D.F., Miller R.M., Schwartz A.R., Levine M.M. Treatment of falciparum malaria with sulfalene and trimethoprim. Am J Trop Med Hyg 1971, 20(6):804-810. PubMed PMID: 4943474. Epub 1971/11/01. eng.
41. Rieckmann K.H., Beaudoin R.L., Cassells J.S., Sell K.W. Use of attenuated sporozoites in the immunization of human volunteers against falciparum malaria. Bull World Health Organ 1979, 57(Suppl. 1):261-265. PubMed PMID: 120773. Pubmed Central PMCID: 2395727. Epub 1979/01/01. eng.
42. The World Medical Association Declaration of Helsinki - ethical principles for medical research involving human subjects 2008, [23/12/2011]. Available from:. http://www.wma.net/en/30publications/10policies/b3/index.html.
43. Woodward WE. Induced typhoid fever and experimental typhoid vaccines - a study of 1886 volunteers.
44. Woodward T.E., Smadel J.E., Ley H.L., Green R., Mankikar D.S. Preliminary report on the beneficial effect of chloromycetin in the treatment of typhoid fever. Ann Intern Med 1948, 29(1):131-134. PubMed PMID: 18869867. Epub 1948/07/01. eng.
45. Kass N.E., Myers R., Fuchs E.J., Carson K.A., Flexner C. Balancing justice and autonomy in clinical research with healthy volunteers. Clin Pharmacol Ther 2007, 82(2):219-227. PubMed PMID: 17410122. Epub 2007/04/06. eng.
46. McDonald J.C. Why prisoners volunteer to be experimental subjects. J Am Med Assoc 1967, 202(6):511-512. PubMed PMID: 4860805. Epub 1967/11/06. eng.
47. Committee on ethical Considerations for Revisions to DHHS Regulations for Protection of Prisoners Involved in Research Ethical considerations for research involving prisoners 2007, Washington, D.C.
48. Hoffman S. Beneficial and unusual punishment: an argument in support of prisoner participation in clinical trials. Indiana Law Rev 2000, 33(2):475-515. PubMed PMID: 16189915. Epub 2005/09/30. eng.
49. Lazzarini Z., Altice F.L. A review of the legal and ethical issues for the conduct of HIV-related research in prisons. AIDS Public Policy J 2000, 15(3-4):105-135. PubMed PMID: 12189712. Epub 2002/08/23. eng.
50. Felix A., Pitt R.M. The pathogenic and immunogenic activities of Salmonella typhi in relation to its antigenic constituents. J Hyg 1951, 49(1):92-110. PubMed PMID: 20475842. Pubmed Central PMCID: 2234993. Epub 1951/03/01. eng.
51. Greisman S.E., Woodward T.E., Hornick R.B., Snyder M.J., Carozza F.A. Typhoid fever: a study of pathogenesis and physiologic abnormalities. Trans Am Clin Climatol Assoc 1961, 73:146-161. PubMed PMID: 13901687. Pubmed Central PMCID: 2249022. Epub 1961/01/01. eng.
52. Hornick R.B., Griesman S. On the pathogenesis of typhoid fever. Arch Intern Med 1978, 138(3):357-359. PubMed PMID: 629628. Epub 1978/03/01. eng.
53. Snyder M.J., Hornick R.B., McCrumb F.R., Morse L.J., Woodward T.E. Asymptomatic typhoidal bacteremia in volunteers. Antimicrob Agents Chemother (Bethesda) 1963, 161:604-607. PubMed PMID: 14274970. Epub 1963/01/01. eng.
54. Glynn J.R., Hornick R.B., Levine M.M., Bradley D.J. Infecting dose and severity of typhoid: analysis of volunteer data and examination of the influence of the definition of illness used. Epidemiol Infect 1995, 115(1):23-30. PubMed PMID: 7641835. Pubmed Central PMCID: 2271553. Epub 1995/08/01. eng.
55. Cirillo V.J. "Winged sponges": houseflies as carriers of typhoid fever in 19th- and early 20th-century military camps. Perspect Biol Med 2006, 49(1):52-63. PubMed PMID: 16489276. Epub 2006/02/21. eng.
56. van den Bergh E.T., Gasem M.H., Keuter M., Dolmans M.V. Outcome in three groups of patients with typhoid fever in Indonesia between 1948 and 1990. Trop Med Int Health 1999, 4(3):211-215. PubMed PMID: 10223217. Epub 1999/05/01. eng.
57. Gonzalez-Escobedo G., Marshall J.M., Gunn J.S. Chronic and acute infection of the gall bladder by Salmonella Typhi: understanding the carrier state. Nat Rev Microbiol 2011, 9(1):9-14. PubMed PMID: 21113180. Epub 2010/11/30. eng.
58. Parry C.M., Hien T.T., Dougan G., White N.J., Farrar J.J. Typhoid fever. N Engl J Med 2002, 347(22):1770-1782. PubMed PMID: 12456854. Epub 2002/11/29. eng.
59. Crosby W.H., Kugler H.W. Intraluminal biopsy of the small intestine; the intestinal biopsy capsule. Am J Dig Dis 1957, 2(5):236-241. PubMed PMID: 13410880.
60. DuPont H.L., Hornick R.B., Weiss C.F., Snyder M.J., Woodward T.E. Evaluation of chloramphenicol acid succinate therapy of induced typhoid fever and rocky mountain spotted fever. N Engl J Med 1970, 282(2):53-57. PubMed PMID: 4982445. Epub 1970/01/08. eng.
61. Levine M.M., DuPont H.L., Hornick R.B., Snyder M.J., Woodward W., Gilman R.H., et al. Attenuated, streptomycin-dependent Salmonella typhi oral vaccine: potential deleterious effects of lyophilization. J Infect Dis 1976, 133(4):424-429. PubMed PMID: 1262709. Epub 1976.
62. Schubart A.F., Hornick R.B., Ewald R.W., Schroeder W.C., Myerburg R.J., Goodman J.S., et al. Changes of Serum complement and properdin levels in experimental typhoid fever. A longitudinal study of the disease including the incubation period and the phase of recovery following treatment with chloramphenicol. J Immunol 1964, 93:387-396. PubMed PMID: 14218595. Epub 1964/09/01. eng.
63. Feigin R.D., Klainer A.S., Beisel W.R., Hornick R.B. Whole-blood amino acids in experimentally induced typhoid fever in man. N Engl J Med 1968, 278(6):293-298. PubMed PMID: 5638347. Epub 1968/02/08. eng.
64. Gilman R.H., Hornick R.B. Duodenal isolation of Salmonella typhi by string capsule in acute typhoid fever. J Clin Microbiol 1976, 3(4):456-457. PubMed PMID: 770502. Pubmed Central PMCID: 274324. Epub 1976/04/01. eng.
65. Avendano A., Herrera P., Horwitz I., Duarte E., Prenzel I., Lanata C., et al. Duodenal string cultures: practicality and sensitivity for diagnosing enteric fever in children. J Infect Dis 1986, 153(2):359-362. PubMed PMID: 3080533. Epub 1986/02/01. eng.
66. Hoffman S.L., Punjabi N.H., Rockhill R.C., Sutomo A., Rivai A.R., Pulungsih S.P. Duodenal string-capsule culture compared with bone-marrow, blood, and rectal-swab cultures for diagnosing typhoid and paratyphoid fever. J Infect Dis 1984, 149(2):157-161. PubMed PMID: 6421940. Epub 1984/02/01. eng.
67. Benavente L., Gotuzzo E., Guerra J., Grados O., Guerra H., Bravo N. Diagnosis of typhoid fever using a string capsule device. Trans R Soc Trop Med Hyg 1984, 78(3):404-406. PubMed PMID: 6380026. Epub 1984/01/01. eng.
68. Parry C.M., Wijedoru L., Arjyal A., Baker S. The utility of diagnostic tests for enteric fever in endemic locations. Expert Rev Anti Infect Ther 2011, 9(6):711-725. PubMed PMID: 21692675. Epub 2011/06/23. eng.
69. Wain J., Hosoglu S. The laboratory diagnosis of enteric fever. J Infect Dev Ctries 2008, 2(6):421-425. PubMed PMID: 19745517. Epub 2008/01/01. eng.
70. Olopoenia L.A., King A.L. Widal agglutination test - 100 years later: still plagued by controversy. Postgrad Med J 2000, 76(892):80-84. PubMed PMID: 10644383. Pubmed Central PMCID: 1741491. Epub 2000/01/22. eng.
71. Pfeiffer R.K.,W. Experimentelle Untersuchunger zur Frage der Schutzimpfung des Menschen gegen Typhus abdominalis. Dtsch Med Wocheschr 1896, 22:735-737.
72. Ashcroft M.T. Immunization against typhoid and paratyphoid fevers. Clin Pediatr (Phila) 1964, 3:385-393. PubMed PMID: 14192459. Epub 1964/07/01. eng.
73. Ashcroft M.T., Singh B., Nicholson C.C., Ritchie J.M., Sorryan E., Williams F. A seven-year field trial of two typhoid vaccines in Guyana. Lancet 1967, 2(7525):1056-1059. PubMed PMID: 4168536. Epub 1967/11/18. eng.
74. Landy M., Gaines S., Seal J.R., Whitside J.E. Antibody responses of man to three types of antityphoid immunizing agents: heat-phenol fluid vaccine, acetone-dehydrated vaccine, and isolated Vi and O antigens. Am J Public Health Nations Health 1954, 44(12):1572-1579. PubMed PMID: 13207484. Pubmed Central PMCID: 1621025. Epub 1954/12/01. eng.
75. Landy M. Studies on Vi antigen. VI. Immunization of human beings with purified Vi antigen. Am J Hyg 1954, 60(1):52-62. PubMed PMID: 13180501.
76. Chuttani C.S., Prakash K., Vergese A., Sharma U., Singha P., Ray B.G., et al. Controlled field trials of oral killed typhoid vaccines in India. Int J Epidemiol 1972, 1(1):39-43. PubMed PMID: 4591283. Epub 1972/01/01. eng.
77. Wahdan M.H., Serie C., Cerisier Y., Sallam S., Germanier R. A controlled field trial of live Salmonella typhi strain Ty 21a oral vaccine against typhoid: three-year results. J Infect Dis 1982, 145(3):292-295. PubMed PMID: 7037982. Epub 1982/03/01. eng.
78. Levine M.M., Ferreccio C., Black R.E., Germanier R. Large-scale field trial of Ty21a live oral typhoid vaccine in enteric-coated capsule formulation. Lancet 1987, 1(8541):1049-1052. PubMed PMID: 2883393.
79. Ferreccio C., Levine M.M., Rodriguez H., Contreras R. Comparative efficacy of two, three, or four doses of TY21a live oral typhoid vaccine in enteric-coated capsules: a field trial in an endemic area. J Infect Dis 1989, 159(4):766-769. PubMed PMID: 2647863. Epub 1989/04/01. eng.
80. Begier E.M., Burwen D.R., Haber P., Ball R., Vaccine Adverse Event Reporting System Working Group Postmarketing safety surveillance for typhoid fever vaccines from the vaccine adverse event reporting system, July 1990 through June 2002. Clin Infect Dis 2004, 38(6):771-779. PubMed PMID: 14999618.
81. Cryz S.J. Post-marketing experience with live oral Ty21a vaccine. Lancet 1993, 341(8836):49-50. PubMed PMID: 8093290.
82. Typhoid vaccine live oral Ty21a 2006, Crucell, [02/12/13]. Product insert. Available from:. http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM142807.pdf.
83. Holt K.E., Parkhill J., Mazzoni C.J., Roumagnac P., Weill F.X., Goodhead I., et al. High-throughput sequencing provides insights into genome variation and evolution in Salmonella Typhi. Nat Genet 2008, 40(8):987-993. PubMed PMID: 18660809. Pubmed Central PMCID: 2652037. Epub 2008/07/29. eng.
84. Dougan G. Genetic sequencing of Quailes strain 2013.
85. Levine M.M. Immunogenicity and efficacy of oral vaccines in developing countries: lessons from a live cholera vaccine. BMC Biol 2010, 8:129. PubMed PMID: 20920375. Pubmed Central PMCID: 2958895. Epub 2010/10/06. eng.
86. Richie E.E., Punjabi N.H., Sidharta Y.Y., Peetosutan K.K., Sukandar M.M., Wasserman S.S., et al. Efficacy trial of single-dose live oral cholera vaccine CVD 103-HgR in North Jakarta, Indonesia, a cholera-endemic area. Vaccine 2000, 18(22):2399-2410. PubMed PMID: 10738097. Epub 2000/03/30. eng.
87. Ram P.K., Naheed A., Brooks W.A., Hossain M.A., Mintz E.D., Breiman R.F., et al. Risk factors for typhoid fever in a slum in Dhaka, Bangladesh. Epidemiol Infect 2007, 135(3):458-465. PubMed PMID: 16893490. Epub 2006/08/09. eng.
88. Marr J.S. Typhoid Mary. Lancet 1999, 353(9165):1714. PubMed PMID: 10335825. Epub 1999/05/21. eng.
89. Van Detta J.A. "Typhoid Mary" meets the ADA: a case study of the "direct threat" standard under the Americans with Disabilities Act. Harv J Law Public Policy 1999, 22(3):849-958. PubMed PMID: 16180287. Epub 2005/09/27. eng.
90. Nga T.V., Parry C.M., Le T., Lan N.P., Diep T.S., Campbell J.I., et al. The decline of typhoid and the rise of non-typhoid salmonellae and fungal infections in a changing HIV landscape: bloodstream infection trends over 15 years in southern Vietnam. Trans R Soc Trop Med Hyg 2012, 106(1):26-34. PubMed PMID: 22137537. Epub 2011/12/06. eng.
91. Peter G., des Vignes-Kendrick M., Eickhoff T.C., Fine A., Galvin V., Levine M.M., et al. Lessons learned from a review of the development of selected vaccines. National Vaccine Advisory Committee. Pediatrics 1999, 104(4 Pt 1):942-950. PubMed PMID: 10506239. Epub 1999/10/03. eng.
92. Patil A.M., Kulkarni M.L., Kulkarni A.M. Baseline widal titres in healthy children. Indian J Pediatr 2007, 74(12):1081-1083. PubMed PMID: 18174641. Epub 2008/01/05. eng.
93. McGregor A.C., Waddington C.S., Pollard A.J. Prospects for prevention of Salmonella infection in children through vaccination. Curr Opin Infect Dis 2013, 26(3):254-262. PubMed PMID: 23591641.
94. Kirkpatrick B.D., McKenzie R., O'Neill J.P., Larsson C.J., Bourgeois A.L., Shimko J., et al. Evaluation of Salmonella enterica serovar Typhi (Ty2 aroC-ssaV-) M01ZH09, with a defined mutation in the Salmonella pathogenicity island 2, as a live, oral typhoid vaccine in human volunteers. Vaccine 2006, 24(2):116-123. PubMed PMID: 16140433. Epub 2005/09/06. eng.
95. Kirkpatrick B.D., Tenney K.M., Larsson C.J., O'Neill J.P., Ventrone C., Bentley M., et al. The novel oral typhoid vaccine M01ZH09 is well tolerated and highly immunogenic in 2 vaccine presentations. J Infect Dis 2005, 192(3):360-366. PubMed PMID: 15995948. Epub 2005/07/05. eng.
96. Tacket C.O., Levine M.M. CVD 908, CVD 908-htrA, and CVD 909 live oral typhoid vaccines: a logical progression. Clin Infect Dis 2007, 45(Suppl. 1):S20-S23. PubMed PMID: 17582563. Epub 2007/07/14. eng.
97. Tacket C.O., Pasetti M.F., Sztein M.B., Livio S., Levine M.M. Immune responses to an oral typhoid vaccine strain that is modified to constitutively express Vi capsular polysaccharide. J Infect Dis 2004, 190(3):565-570. PubMed PMID: 15243933. Epub 2004/07/10. eng.
98. Wahid R., Pasetti M.F., Maciel M., Simon J.K., Tacket C.O., Levine M.M., et al. Oral priming with Salmonella Typhi vaccine strain CVD 909 followed by parenteral boost with the S. Typhi Vi capsular polysaccharide vaccine induces CD27+IgD-S. Typhi-specific IgA and IgG B memory cells in humans. Clin Immunol 2011, 138(2):187-200. PubMed PMID: 21146460. Pubmed Central PMCID: 3035995. Epub 2010/12/15. eng.
99. Lin F.Y., Ho V.A., Khiem H.B., Trach D.D., Bay P.V., Thanh T.C., et al. The efficacy of a Salmonella typhi Vi conjugate vaccine in two-to-five-year-old children. N Engl J Med 2001, 344(17):1263-1269. PubMed PMID: 11320385.
100. Pulickal A.S., Pollard A.J. Vi polysaccharide-protein conjugate vaccine for the prevention of typhoid fever in children: hope or hype?. Expert Rev Vaccines 2007, 6(3):293-295. PubMed PMID: 17542742. Epub 2007/06/05. eng.
101. DuPont H.L., Hornick R.B., Snyder M.J., Libonati J.P., Formal S.B., Gangarosa E.J. Immunity in shigellosis. II. Protection induced by oral live vaccine or primary infection. J Infect Dis 1972, 125(1):12-16. PubMed PMID: 4550416. Epub 1972/01/01. eng.
102. Levine M.M., Caplan E.S., Waterman D., Cash R.A., Hornick R.B., Snyder M.J. Diarrhea caused by Escherichia coli that produce only heat-stable enterotoxin. Infect Immun 1977, 17(1):78-82. PubMed PMID: 328397. Pubmed Central PMCID: 421084. Epub 1977/07/01. eng.
103. DuPont H.L., Hornick R.B., Snyder M.J., Libonati J.P., Woodward T.E. Immunity in typhoid fever: evaluation of live streptomycin-dependent vaccine. Antimicrob Agents Chemother (Bethesda) 1970, 10:236-239. PubMed PMID: 4939733. Epub 1970/01/01. eng.